Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for HCC by harnessing the immune system—particularly CD8+ T cells, which are pivotal in recognizing and destroying cancer cells through their cytotoxic activity 51, 52. The gene discussed is CD8A; the disease is cancer.